Orchestra Operating Cycle from 2010 to 2026
| OBIO Stock | 3.92 0.06 1.51% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 290.04 | Current Value 191.58 | Quarterly Volatility 64.82971249 |
Check Orchestra BioMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Orchestra BioMed's main balance sheet or income statement drivers, such as Net Interest Income of 4.1 M, Interest Income of 2.1 M or Depreciation And Amortization of 249.7 K, as well as many indicators such as Price To Sales Ratio of 52.76, Dividend Yield of 0.0 or PTB Ratio of 4.22. Orchestra financial statements analysis is a perfect complement when working with Orchestra BioMed Valuation or Volatility modules.
Orchestra | Operating Cycle | Build AI portfolio with Orchestra Stock |
Evaluating Orchestra BioMed's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Orchestra BioMed Holdings's fundamental strength.
Latest Orchestra BioMed's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Orchestra BioMed Holdings over the last few years. It is Orchestra BioMed's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Orchestra BioMed's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Orchestra Operating Cycle Regression Statistics
| Arithmetic Mean | 207.26 | |
| Geometric Mean | 196.76 | |
| Coefficient Of Variation | 31.28 | |
| Mean Deviation | 47.72 | |
| Median | 184.44 | |
| Standard Deviation | 64.83 | |
| Sample Variance | 4,203 | |
| Range | 255 | |
| R-Value | 0.46 | |
| Mean Square Error | 3,539 | |
| R-Squared | 0.21 | |
| Significance | 0.06 | |
| Slope | 5.89 | |
| Total Sum of Squares | 67,246 |
Orchestra Operating Cycle History
About Orchestra BioMed Financial Statements
Orchestra BioMed investors utilize fundamental indicators, such as Operating Cycle, to predict how Orchestra Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 290.04 | 191.58 |
Pair Trading with Orchestra BioMed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.Moving against Orchestra Stock
| 0.63 | EQ | Equillium | PairCorr |
| 0.62 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.61 | DRTS | Alpha Tau Medical | PairCorr |
| 0.57 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.52 | GXEA | Galapagos NV Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Orchestra BioMed Correlation against competitors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Will Biotechnology sector continue expanding? Could Orchestra diversify its offerings? Factors like these will boost the valuation of Orchestra BioMed. Anticipated expansion of Orchestra directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Orchestra BioMed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
Orchestra BioMed Holdings's market price often diverges from its book value, the accounting figure shown on Orchestra's balance sheet. Smart investors calculate Orchestra BioMed's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Orchestra BioMed's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Orchestra BioMed's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Orchestra BioMed should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.